Legend Biotech Corp ADR (LEGN)
Industry Biotechnology
This stock can be held in an Investment Account
Sell
$27.61
Buy
$27.65
$-0.05 (-0.18%)
Prices updated at 16 May 2025, 16:17 BST
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| 49m | 57m | 75m | 69m | 117m | 285m | 627m | |
| - | - | 75m | 69m | 52m | 141m | 393m | |
| -15m | -135m | -227m | -392m | -456m | -439m | -303m | |
| - | -236.39 | -302.39 | -569.97 | -389.40 | -154.13 | -48.35 | |
| -3m | -133m | -266m | -404m | -446m | -518m | -177m | |
| 149,000 | -125m | -298m | -392m | -417m | -478m | -113m | |
| Sales, General and administrative | 4m | 32m | 73m | 150m | 174m | 201m | 284m |
| Interest expenses | 82,000 | 223,000 | 195,000 | 900,000 | 11m | 22m | 22m |
| Provision for income taxes | 1m | 3m | -42m | -4m | 625,000 | -2m | 19m |
| Operating expenses | 64m | 193m | 302m | 461m | 507m | 580m | 696m |
| Income before taxes | -2m | -130m | -308m | -407m | -446m | -520m | -158m |
| Net income available to common shareholders | -3m | -133m | -266m | -404m | -446m | -518m | -177m |
| -0.027781 | -1.028 | -2.56 | -2.74 | -2.8 | -2.94 | -0.96 | |
| Net interest income | 6m | 4m | -1m | 71,000 | -3m | 33m | 40m |
| Advertising and promotion | - | - | - | - | - | - | - |
| Net investment income, net | - | - | - | - | - | - | - |
| Realised capital gains (losses), net | - | - | - | - | - | - | - |
| Total benefits, claims and expenses | - | - | - | - | - | - | - |
| Earnings per share (diluted) | -0.027781 | -1.028 | -2.56 | -2.74 | -2.8 | -2.94 | -0.96 |
| Free cash flow per share | - | - | -2.0015 | -1.7814 | -2.1211 | -2.1573 | -0.9656 |
| Book value/share | - | - | 2.5179 | 1.4645 | 2.6569 | 7.3642 | 6.0774 |
| Debt equity ratio | - | - | 0.003194 | 0.159352 | 0.377491 | 0.260112 | 0.332334 |
Balance sheet
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Current assets | 327m | 207m | 593m | 949m | 1,099m | 1,498m | 1,284m |
| Current liabilities | 159m | 128m | 161m | 280m | 298m | 216m | 278m |
| Total capital | 9m | -123m | 280m | 592m | 1,005m | 1,533m | 1,342m |
| Total debt | 4m | 6m | 3m | 123m | 285m | 329m | 351m |
| Total equity | 9m | -123m | 280m | 471m | 744m | 1,251m | 1,041m |
| Total non current liabilities | - | - | - | - | - | - | - |
| Loans | - | - | - | 120m | 261m | 281m | 301m |
| Total assets | 429m | 288m | 721m | 1,118m | 1,331m | 1,849m | 1,670m |
| Total liabilities | - | - | - | - | - | - | - |
| Cash and cash equivalents | 210m | 83m | 456m | 689m | 786m | 1,278m | 287m |
| Common stock | 259m | 259m | 266m | 308m | 330m | 364m | 367m |
Cash flow
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash at beginning of period | 2m | 210m | 83m | 456m | 689m | 786m | 1,278m |
| Cash dividends paid | - | - | - | - | - | - | - |
| 287m | -122m | -273m | -246m | -224m | -416m | -158m | |
| Investments (gains) losses | -102m | -59m | -24m | -195m | -77m | 93m | -851m |
| 210m | 83m | 456m | 689m | 786m | 1,278m | 287m | |
| Net income | - | - | - | - | - | - | - |
| 308m | -83m | -223m | -198m | -201m | -393m | -144m | |
| -21m | -39m | -50m | -47m | -22m | -23m | -14m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
